At El Capitan Biosciences (ECB), our mission is to harness advanced machine learning algorithms to discover novel clinically-significant biomarkers in stool samples to zero-out the incident of CRC. By addressing the critical barriers that deter regular screening, such as accessibility, cost, and convenience, our innovative approach seeks to enhance early disease detection when follow-up treatment is both clinically and cost-effective.